KNOW YOUR NUMBERS! (2.10.2023) Save

Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.

1. Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://bit.ly/3DSNMmL

2. 211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare  https://t.co/6EbM3Vx0Ei

3. Treatment failures studied in 718 RA pts - csDMARDs D/Cs intolerance (22%), inefficacy (20%), acute Rxns (5%), severe infx(0.6%) - bDMARDs D/Cs inefficacy (29%), intolerance (10%), acute Rxns (6%), severe infx (1.5%) - Multi-drug failure 5.7-8.4% https://t.co/FdoP77uELe

4. NLRP12 is a negative regulator innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/PjTQNHhduB

5. GRAPPA Recommendations for Treating Enthesitis in PsA GRAPPA has provided new updates to the mgmt of enthesitis in patients with PsA, affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes. https://t.co/AC6KHGMeo0

6. Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3% with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, calcinosis (but not renal crisis, ILD, or pulmonary HTN https://t.co/Usrfr0XcCJ

7. High- Versus Low-Dose Exercise Therapy for Knee Osteoarthritis The Annals of Internal medicine has reported the results of high-dose versus low-dose exercise therapy demonstrating no benefits from more intense exercise. https://t.co/BtqeYWKG34

8. Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria: - 3 pts rash - 3pts fever ≥ 39C - 2 pts pharyngitis - 2 pts arthritis - 2 pts NLR ≥ 4 - 1 pt glycosyl ferritin ≤ 20% 7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/Amew1RHaA1

9. Metanalysis of Steroid Tx & metabolic events (118 studies & 17113 pts) showed an increased risk: - hyperglycemia 10% (esp lung dz 22%) - severe hyperglyc. 5%, HTN 6%, Wt gain 13% , hyperlipid 8% - Incr risk of hyperglyc (OR 2), HTN (1.7), Wt gain (5.2) https://t.co/E54IB3YVfn

10. About 1 mo ago we reported US drug makers would increase price of 350 drugs; now it seems US Pharma has raised list prices of 983 arthritis, cancer and other drugs by an average of 5.6% in Jan 2023; as industry faces new federal laws to control costs https://t.co/HkdDurbNrQ

11. Early ph II Pilot trial of 30 Systemic Sclerosis Pts using a new antifibrotic FT011 400mg vs 200mg v PBO x 12 wks showed CRISS score improved by 60% (400mg; (p=0.02 ) or 20% (200mg) at 12wks. An OL extension is planned for 9 mos @400 mg/d. https://t.co/8R51VLUbvX

12. Does Methotrexate Increase Skin Cancer Risk?

13. Deucravacitinib - Effective in Systemic Lupus Erythematosus

14. Join us at RheumNow Live this March!